156 related articles for article (PubMed ID: 10418719)
1. Prognostic significance of marker half-life during chemotherapy in non-seminomatous germ cell testicular tumors.
Inanç SE; Meral R; Darendeliler E; Yasasever V; Onat H
Acta Oncol; 1999; 38(4):505-9. PubMed ID: 10418719
[TBL] [Abstract][Full Text] [Related]
2. Tumour marker concentration at the start of chemotherapy is a stronger predictor of treatment failure than marker half-life: a study in patients with disseminated non-seminomatous testicular cancer.
de Wit R; Sylvester R; Tsitsa C; de Mulder PH; Sleyfer DT; ten Bokkel Huinink WW; Kaye SB; van Oosterom AT; Boven E; Vermeylen K; Stoter G
Br J Cancer; 1997; 75(3):432-5. PubMed ID: 9020492
[TBL] [Abstract][Full Text] [Related]
3. Serum tumor marker decline is an early predictor of treatment outcome in germ cell tumor patients treated with cisplatin and ifosfamide salvage chemotherapy.
Murphy BA; Motzer RJ; Mazumdar M; Vlamis V; Nisselbaum J; Bajorin D; Bosl GJ
Cancer; 1994 May; 73(10):2520-6. PubMed ID: 7513603
[TBL] [Abstract][Full Text] [Related]
4. AFP and HCG in germ cell tumors.
Bassetto MA; Franceschi T; Lenotti M; Parise G; Pancheri F; Sabbioni R; Zaninelli M; Cetto GL
Int J Biol Markers; 1994; 9(1):29-32. PubMed ID: 7519651
[TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of early serum tumor marker half-life in metastatic testicular teratoma.
Stevens MJ; Norman AR; Dearnaley DP; Horwich A
J Clin Oncol; 1995 Jan; 13(1):87-92. PubMed ID: 7528272
[TBL] [Abstract][Full Text] [Related]
6. The value of AFP and HCG half lives in predicting the efficacy of combination chemotherapy in patients with non-seminomatous germ cell tumors of the testis.
Willemse PH; Sleijfer DT; Schraffordt Koops H; De Bruijn HW; Oosterhuis JW; Brouwers TM; Ockhuizen T; Marrink J
Oncodev Biol Med; 1981; 2(1-2):129-34. PubMed ID: 6170953
[TBL] [Abstract][Full Text] [Related]
7. Serum alpha-fetoprotein surge after the initiation of chemotherapy for non-seminomatous testicular cancer has an adverse prognostic significance.
de Wit R; Collette L; Sylvester R; de Mulder PH; Sleijfer DT; ten Bokkel Huinink WW; Kaye SB; van Oosterom AT; Boven E; Stoter G
Br J Cancer; 1998 Nov; 78(10):1350-5. PubMed ID: 9823978
[TBL] [Abstract][Full Text] [Related]
8. Serum tumor marker half-life during chemotherapy in patients with germ cell tumors.
Bosl GJ; Head MD
Int J Biol Markers; 1994; 9(1):25-8. PubMed ID: 7519650
[TBL] [Abstract][Full Text] [Related]
9. Predicting outcome to chemotherapy in patients with germ cell tumors: the value of the rate of decline of human chorionic gonadotrophin and alpha-fetoprotein during therapy.
Mazumdar M; Bajorin DF; Bacik J; Higgins G; Motzer RJ; Bosl GJ
J Clin Oncol; 2001 May; 19(9):2534-41. PubMed ID: 11331333
[TBL] [Abstract][Full Text] [Related]
10. Detection of vital germ cell tumor cells in short-term cell cultures of primary tumors and of retroperitoneal metastasis--clinical implications.
Otto T; Virchow S; Fuhrmann C; Steinberg F; Streffer C; Goepel M; Rübben H
Urol Res; 1997; 25(2):121-4. PubMed ID: 9144879
[TBL] [Abstract][Full Text] [Related]
11. Acute changes of alpha-fetoprotein and human chorionic gonadotropin during induction chemotherapy of germ cell tumors.
Vogelzang NJ; Lange PH; Goldman A; Vessela RH; Fraley EE; Kennedy BJ
Cancer Res; 1982 Nov; 42(11):4855-61. PubMed ID: 6181870
[TBL] [Abstract][Full Text] [Related]
12. The growth rate of metastatic nonseminomatous germ cell testicular tumours measured by marker production doubling time--II. Prognostic significance in patients treated by chemotherapy.
Price P; Hogan SJ; Bliss JM; Horwich A
Eur J Cancer; 1990 Apr; 26(4):453-7. PubMed ID: 1694087
[TBL] [Abstract][Full Text] [Related]
13. Prognostic implications of tumour marker analysis in non-seminomatous germ cell tumours with poor prognosis metastatic disease.
Gerl A; Clemm C; Lamerz R; Mann K; Wilmanns W
Eur J Cancer; 1993; 29A(7):961-5. PubMed ID: 7684597
[TBL] [Abstract][Full Text] [Related]
14. Personalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumours (GETUG 13): a phase 3, multicentre, randomised trial.
Fizazi K; Pagliaro L; Laplanche A; Fléchon A; Mardiak J; Geoffrois L; Kerbrat P; Chevreau C; Delva R; Rolland F; Theodore C; Roubaud G; Gravis G; Eymard JC; Malhaire JP; Linassier C; Habibian M; Martin AL; Journeau F; Reckova M; Logothetis C; Culine S
Lancet Oncol; 2014 Dec; 15(13):1442-1450. PubMed ID: 25456363
[TBL] [Abstract][Full Text] [Related]
15. The growth rate of metastatic non-seminomatous germ cell testicular tumours measured by marker production doubling time--I. Theoretical basis and practical application.
Price P; Hogan SJ; Horwich A
Eur J Cancer; 1990 Apr; 26(4):450-3. PubMed ID: 1694086
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of pregnancy-specific beta 1-glycoprotein in patients with non-seminomatous testicular germ cell tumors.
de Bruijn HW; Suurmeijer AJ; Sleijfer DT; Koops HS; Ockhuizen T; Willemse PH; Marrink J
Eur J Cancer Clin Oncol; 1982 Oct; 18(10):911-6. PubMed ID: 6186495
[TBL] [Abstract][Full Text] [Related]
17. Testicular tumour markers in tissue correlated to serum levels and clinical stage.
Alm P; Hultberg B; Olsson AM
Scand J Urol Nephrol; 1984; 18(4):283-8. PubMed ID: 6209794
[TBL] [Abstract][Full Text] [Related]
18. Importance of a new tumor marker TRA-1-60 in the follow-up of patients with clinical stage I nonseminomatous testicular germ cell tumors.
Gels ME; Marrink J; Visser P; Sleijfer DT; Droste JH; Hoekstra HJ; Andrews PW; Schraffordt Koops H
Ann Surg Oncol; 1997 Jun; 4(4):321-7. PubMed ID: 9181232
[TBL] [Abstract][Full Text] [Related]
19. Is serum tumor marker half-life a guide to prognosis in metastatic nonseminomatous germ cell tumors?
Gerl A; Lamerz R; Mann K; Clemm C; Wilmanns W
Anticancer Res; 1997; 17(4B):3047-9. PubMed ID: 9329598
[TBL] [Abstract][Full Text] [Related]
20. [The role of tumor markers in the treatment of germ cell tumor].
Niwakawa M; Tobisu K
Gan To Kagaku Ryoho; 2001 Aug; 28(8):1159-65. PubMed ID: 11525037
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
